Studies such as CheckMate 066/067 and KEYNOTE-010 have demonstrated that rechallenge with nivolumab and pembrolizumab resulted in lesion shrinkage and significant OS improvements in patients with advanced melanoma and PD-L1-positive advanced non-small-cell lung cancer (NSCLC), with no additional AEs reported (53–56). Here, CD274 is linked to melanoma.